Cited 22 times since 2006 (1.2 per year) source: EuropePMC Acta cardiologica, Volume 61, Issue 3, 1 1 2006, Pages 327-331 Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Maitland-van der Zee AH, Jukema JW, Zwinderman AH, Hallman DM, De Boer A, Kastelein JJ, De Knijff P
Objective
[corrected] The influence ofApoE polymorphism on the efficacy of statins in lowering plasma lipids and lipoproteins and improving angiographic parameters was assessed.
Methods
ApoE genotypes were studied in a group (n = 815) of well-characterised male coronary artery disease (CAD) patients who participated in the lipid-lowering regression study 'Regression Growth Evaluation Statin Study (REGRESS)'.
Results
There was a significant interaction between treatment (placebo/pravastatin) and APOE genotype when lipid levels were considered, APOE2 + carriers exhibited the largest improvement of HDL levels (+0.15 mmol/l) and LDL/HDL ratios (-0.60) compared with APOE3 + (+ 0.06 mmol/l, -0.043, respectively) and APOE4 + carriers (+ 0.07 mmol/l, -0.040). In contrast,APOE2 + allele carriers had the least effect in terms of angiographic parameters, although the difference was not statistically significant.
Conclusions
The effects of statins in subjects with different ApoE genotypes were different with regard to the lipoprotein profile, but not with regard to angiographic parameters.
